Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-05-03
1999-08-24
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 9, 514 12, 530317, 530324, A61K 3816, A61K 3812, C07K 764, C07K 700
Patent
active
059424893
ABSTRACT:
A peptide selected from the group having the formulae:
.alpha.) X-R.sup.1 -R.sup.2 -R.sup.3 -R.sup.4 -R.sup.5 -R.sup.6 -Thr-R.sup.8 -R.sup.9 -R.sup.10 -R.sup.11 -R.sup.12 -Val-Leu-R.sup.15 -Gln-Leu-Ser-R.sup.19 -R.sup.20 -R.sup.21 -Leu-Leu-Gln-Asp-Ile-R.sup.27 -R.sup.28 -R.sup.29, wherein X is H, Ac, Aqc, IAc, BrProp, For, Ibu, Nac, 2-Nac, 1- or 2-Npt, 1- or 2-Npr, PhAc, Fpr, or any other aromatic or nonpolar acyl group, R.sup.1 is Tyr, His or Phe(Y), in which Y=H, F, Cl, Br, NO.sub.2, CH.sub.3 or OCH.sub.3, R.sup.2 is D-Arg, D-Cit, D-Har, D-Lys, D-Tic or D-Orn, R.sup.3 is Asp, D-Asp, Ala, D-Ala or Gly, R.sup.4 is Ala, Abu or Gly, R.sup.5 is Ile, Ala or Gly, R.sup.6 is Phe, Tic, Ala, Pro, Tpi, Nal or Phe(Y), in which Y=H, F, Cl, Br, NO.sub.2, NH.sub.2, CH.sub.3 or OCH.sub.3, R.sup.8 is Asn, Gln, Ser, Thr, Val, Leu, Ile, Ala, D-Ala, D-Asn, D-Gln, D-Thr, D-Leu, Abu, D-Abu, Nle, or Alb, R.sup.9 is Ser, R.sup.10 is Tyr or Phe(Y), in which Y=H, F, Cl, Br, NO.sub.2, CH.sub.3 or OCH.sub.3, R.sup.11 is Arg, D-Arg, or Cit, R.sup.12 is Lys, D-Lys, Cit, D-Cit, Orn, D-Orn, Nle or Ala, R.sup.15 is Gly, Ala, Abu or Gln, R.sup.19 is Ala or Abu, R.sup.20 is Arg, D-Arg or Cit, R.sup.21 is Lys, D-Lys, Orn or Cit, R.sup.27 is Met, Nle or Abu, R.sup.28 is Ser, Asn, Ala or Abu, R.sup.29 is Agm, Arg-NH.sub.2, Arg-OH, Cit-NH.sub.2, Cit-OH, Har-NH.sub.2 or Har-OH, and
.beta.) X-A.sup.1 -B.sup.2 -A.sup.3 -R.sup.4 -R.sup.5 -R.sup.6 -Thr-A.sup.8 Ser-R.sup.10 -R.sup.11 -B.sup.12 -Val-Leu-R.sup.15 -A.sup.16 -A.sup.17 -Ser-R.sup.19 -B.sup.20 -B.sup.21 -Leu-Leu-Gln-A.sup.26 -Ile-R.sup.27 -R.sup.28 -R.sup.29, wherein a lactam bridge is formed between any one of the pairs of positions 1,2; 2,3; 8,12; 16,20; 17-21; 21,25; 25,29 or both 8,12 and 21,25 positions, and X is H, Ac, Aqc, IAc, BrProp, For, Ibu, Nac, 2-Nac, 1- or 2-Npt, 1- or 2-Npr, PhAc, Fpr, or any other aromatic or nonpolar acyl group, A is Glu, D-Glu, Gln, Asp, D-Asp, Asn, Abu, Leu, Tyr, His, Phe(Y), in which Y=H, F, cl, Br, NO.sub.2, NH.sub.2, CH.sub.3 or OCH.sub.3, Ser, Thr, Val, Ile, Ala, D-Ala, D-Asn, D-Gln, D-Thr, D-Leu, Abu, D-Abu, Nle, or Aib, B is Lys, D-Lys, Arg, D-Arg,Orn, D-Orn, or Agm; R.sup.4 is Ala, Abu or Gly, R.sup.5 is Ile, Ala or Gly, R.sup.6 is Phe, Tic, Tpi, Nal or Phe(Y), in which Y=H, F, Cl, Br, NO.sub.2, NH.sub.2 CH.sub.3 or OCH.sub.3, R.sup.10 is Tyr or Phe(Y), in which Y=H, F, Cl, Br, NO.sub.2, NH.sub.2 CH.sub.3 or OCH.sub.3, R.sup.15 is Gly, Ala, Abu or Gin, R.sup.27 is Met, Nle or Abu, R.sup.28 is Ser, Asn, Asp, Ala or Abu, and pharmaceutically acceptable salts thereof.
REFERENCES:
patent: 4377515 (1983-03-01), Veber et al.
patent: 4493934 (1985-01-01), Veber et al.
patent: 5358934 (1994-10-01), Borovsky et al.
patent: 5516759 (1996-05-01), Swenson et al.
patent: 5550212 (1996-08-01), Zarandi et al.
patent: 5723614 (1998-03-01), Bathe et al.
Rekasi, Z. A method for evaluation of activity of antagonistic analogs of growth hormone-releasing hormone in a superfusion system. Proc. Natl. Acad. Sci. U. S. A. 90(6), 2146-2149, Jun. 1993.
Zarandi, M.; Horvath, J. E.; Halmos, G.; Pinski, J., Nagy, A.; Groot, K,; Rekasi, Z.; Schally, A. V. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc. Natl. Acad. Sci. U. S. A. (1994), 91(25), Aug. 1, 1994.
Sato, K., Hotta, M., Kageyama J., Hu, H., Dong, M., Ling, N. Synthetic analogs of growth hormone-releasing factor with antagonistic activity in vitro. Biochem. Biophys. Res. Commun. 167(1), 360-6, Jan. 1990.
Sato, K., Hotta, M., Kageyama, J., Chiang, T., Chang; H., Hsiao Y., Dong, M., Ling, N. Structure-activity relations of growth hormone-releasing factor. Pept. Chem., vol. Date 1988, 26th, 85-90, 1989.
Schally A. et al. In: Growth hormone secretagogues in clinical practice. B. Bercu & R. Walker, Eds. Marcel Dekker, N.Y., chapter 10, pp. 145-162, Jan. 1998.
Fry D.C. et al. Biopolymers, 32(6) 649-666, Jun. 1992.
Felix A.M. et al. Abstr.Pap.Am.Chem.Soc. (199 Meet., Pt. 1, BIOL130,) Feb. 1990.
Notification of Transmittal of Search Report, Oct. 1, 1997.
Proc. Natl. Acad Sci, vol. 91, pp. 12298-12303, Dec. 1994.
Peptides, vol. 18, No. 3, pp. 423-440, 1997.
Peptides, vol. 18, No. 3, pp. 431-438, 1997.
Schally Andrew V.
Toth Katalin
Zarandi Marta
Behr Esq. Omri M.
Borin Michael
The Administrators of the Tulane Educational Fund
Tsang Cecilia J.
LandOfFree
HGH-RH(1-29)NH2 analogues having antagonistic activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HGH-RH(1-29)NH2 analogues having antagonistic activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HGH-RH(1-29)NH2 analogues having antagonistic activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-467063